DSIP
Delta Sleep-Inducing Peptide · Sleep & Stress Modulator
DSIP is a naturally occurring nonapeptide discovered in 1974 in rabbit brain. Originally isolated for sleep-promoting properties, it has diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation without traditional sedative effects.
Overview
DSIP is a naturally occurring nonapeptide discovered in 1974 in rabbit brain. Originally isolated for sleep-promoting properties, it has diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation without traditional sedative effects.
Modulates multiple neurotransmitter systems including GABA enhancement, NMDA receptor interaction, and endogenous opioid system modulation. Also regulates hypothalamic-pituitary-adrenal axis for stress response.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Promotes delta wave sleep, the most restorative sleep phase for physical recovery.
Reduces sleep latency and nocturnal awakenings without morning grogginess.
Supports natural sleep cycles rather than forcing sedation like traditional sleep aids.
Helps regulate cortisol and stress response through HPA axis modulation.
Supports emotional balance without sedation.
May help reduce anxiety through neuromodulatory effects.
Significantly reduced pain levels in 6 of 7 patients with chronic pain conditions.
Helps manage withdrawal symptoms in alcohol and opioid-dependent patients.
Supports post-training recovery through enhanced sleep quality.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Nonapeptide
- Chain length
- 9 residues
- Molecular weight
- 848.81 Da
- Half-life
- ~15 min
- Typical dose
- 100-300mcg
- Frequency
- 1x daily
- Cycle length
- 5-10 days
- Storage
- 2-8°C refrigerated
Molecular data
- Type
- Nonapeptide
- Molecular weight
- 848.81 Da
- Chain length
- 9 residues
- Half-life
- 15 min
WAGGDASGEDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Sleep enhancement | SubQ | 100-200mcg | Once nightly |
| Chronic pain support | SubQ or IV | 250-300mcg | Daily |
| Stress management | SubQ | 150mcg | Evening |
| Withdrawal support | IV preferred | 200-300mcg | Twice daily |
| Athletic recovery | SubQ | 100-150mcg | Post-training |
| Sleep induction | Nasal spray | 200-300mcg | Once at bedtime |
| Stress relief | Nasal spray | 150-200mcg | Twice daily |
| Neuroprotection | Nasal spray | 300-400mcg | Daily |
Interactions
Both regulate sleep-wake cycles; complementary benefits.
DSIP enhances GABA - watch for excessive sedation.
Can combine for comprehensive stress management.
Complementary anxiolytic effects.
Different mechanisms; can optimize 24-hour function.
May modulate opioid receptors; requires professional supervision.
No direct interaction; DSIP may support natural GH release during sleep.
Both support circadian regulation and sleep quality.
Quality checklist
- ✓White lyophilized powder before reconstitution
- ✓Clear and colorless solution when properly mixed
- ✓Reputable source with third-party testing
- !Short stability period - use within 14 days when reconstituted
- !Protect from light exposure and temperature fluctuations
- !Limited nasal formulation stability (use within 10 days)
- ×Yellow or cloudy solution indicates degradation or contamination
- ×Discolored powder
What to expect
Safety
- Generally well-tolerated with minimal side effects
- Mild drowsiness or dizziness initially (some users)
- Occasional headaches in sensitive individuals
- No tolerance or dependence reported in studies
- Excessive daytime sedation
- Paradoxical insomnia or agitation
- Persistent headaches
- Any allergic reactions
- Mood changes or depression
- Unusual dreams causing distress
- Avoid driving until effects are known
- Pregnancy or breastfeeding
FAQ
How quickly does DSIP improve sleep compared to melatonin?
DSIP acts within 30-60 minutes of injection with noticeable sleep pressure by the first dose. It works faster than melatonin (which takes 1-2 hours) and promotes natural delta-wave sleep architecture rather than sedation. Most users report deeper, more restorative sleep from night one of use.
Will DSIP cause dependence or tolerance like sleeping pills?
No dependence or tolerance has been reported with DSIP in clinical studies, unlike traditional sedatives. Its naturally occurring structure and neuromodulatory mechanism (GABA enhancement, HPA axis modulation) work through physiological pathways rather than receptor desensitization, making it suitable for short cycles without habituation concerns.
Can DSIP help with chronic pain like the research suggests?
One clinical study found 6 of 7 chronic pain patients experienced significant pain reduction with IV DSIP (25 nmol for 10 days). It works through multiple pathways including endogenous opioid modulation and stress reduction. However, human data is limited primarily to small studies, so pain management requires medical oversight.
Is DSIP useful for managing withdrawal from alcohol or opioids?
Yes, research shows DSIP is remarkably effective for withdrawal management—87% of alcoholics and 97% of opioid addicts showed beneficial effects in clinical trials using IV administration (25 nmol/kg). It reduces withdrawal symptoms through immediate onset and HPA axis normalization, making it relevant for addiction medicine.
References
- 1Acute and Delayed Effects of DSIP (Delta Sleep-Inducing Peptide) on Human Sleep BehaviorSchneider-Helmert D, Schoenenberger GA · International Journal of Peptide and Protein Research · 1983
6 normal volunteers; 25 nmol/kg IV DSIP induced 59% increase in total sleep time within 130 minutes; improved subsequent night sleep efficiency without sedation.
reviewPubMed 6895513 ↗ - 2Therapeutic Effects of Delta-Sleep-Inducing Peptide (DSIP) in Patients with Chronic, Pronounced Pain Episodes: A Clinical Pilot StudySchoenenberger GA, Schneider-Helmert D · European Neurology · 1984
7 patients with chronic pain (migraine, vasomotor headaches); 25 nmol IV DSIP for 10 days significantly reduced pain levels in 6 of 7 patients.
human-pilotPubMed 6548970 ↗ - 3DSIP in the Treatment of Withdrawal Syndromes from Alcohol and OpiatesDick P, Costa C, Fayolle K, et al. · European Neurology · 1984
107 patients (47 alcohol, 60 opiate withdrawal); DSIP (25 nmol/kg IV) produced beneficial effects in 97% of opiate addicts and 87% of alcoholics with immediate onset and lasting symptom relief.
reviewPubMed 6548969 ↗ - 4Successful Treatment of Withdrawal Symptoms with Delta Sleep-Inducing PeptideLarbig W, Gerber WD, Kluck M, Schoenenberger GA · Neuropsychobiology · 1984
DSIP (25 nmol/kg IV) administered to 67 patients; beneficial effect in 48 of 49 evaluable patients (22 alcoholics and 26 of 27 opiate addicts) with good tolerance.
reviewPubMed 6328354 ↗ - 5Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients: A Double-Blind StudySchneider-Helmert D · Neuropsychobiology · 1992
Double-blind placebo-controlled study; DSIP (15-30 nmol for 6 consecutive nights) showed higher sleep efficiency and shorter sleep latency, though statistical effects were weak.
human-rctPubMed 1299794 ↗ - 6Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats After Focal StrokeTukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. · Pharmaceutics · 2021
120 mcg/kg intranasal DSIP for 8 days accelerated motor function recovery (rotarod test) after focal stroke in rats; brain infarction was smaller but not statistically significant.
animalPubMed 34500605 ↗